Blueprint Medicines Corporation
BPMC · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Market Cap | $5,629,236 | $5,547,192 | $5,862,743 | $6,862,400 |
| - Cash | $122,245 | $102,014 | $89,356 | $54,771 |
| + Debt | $122,749 | $469,106 | $471,496 | $740,349 |
| Enterprise Value | $5,629,740 | $5,914,284 | $6,244,883 | $7,547,978 |
| Revenue | $149,413 | $146,366 | $128,184 | $138,157 |
| % Growth | 2.1% | 14.2% | -7.2% | – |
| Gross Profit | $146,611 | $138,919 | $126,252 | $126,947 |
| % Margin | 98.1% | 94.9% | 98.5% | 91.9% |
| EBITDA | -$41,086 | -$27,115 | -$33,374 | -$29,475 |
| % Margin | -27.5% | -18.5% | -26% | -21.3% |
| Net Income | $496 | -$49,956 | -$56,276 | -$49,994 |
| % Margin | 0.3% | -34.1% | -43.9% | -36.2% |
| EPS Diluted | 0.01 | -0.79 | -0.89 | -0.8 |
| % Growth | 101.3% | 11.2% | -11.2% | – |
| Operating Cash Flow | -$54,479 | -$29,364 | -$13,637 | -$48,072 |
| Capital Expenditures | -$1,831 | -$932 | -$25 | -$2,569 |
| Free Cash Flow | -$56,310 | -$30,296 | -$13,662 | -$50,641 |